Invention Grant
- Patent Title: Treatment of ophthalmic conditions by selectively removing senescent cells from the eye
-
Application No.: US15827539Application Date: 2017-11-30
-
Publication No.: US10010546B2Publication Date: 2018-07-03
- Inventor: Remi-Martin Laberge , Judith Campisi , Marco Demaria , Nathaniel David , Alain Philippe Vasserot , James L. Kirkland , Tamar Tchkonia , Yi Zhu , Darren J. Baker , Bennett G. Childs , Jan M. A. van Deursen
- Applicant: Buck Institute for Research on Aging , Mayo Foundation for Medical Education and Research , Unity Biotechnology, Inc.
- Applicant Address: US CA Brisbane US CA Novato US MN Rochester
- Assignee: Unity Biotechnology, Inc.,Buck Institute for Research on Aging,Mayo Foundation for Medical Education and Research
- Current Assignee: Unity Biotechnology, Inc.,Buck Institute for Research on Aging,Mayo Foundation for Medical Education and Research
- Current Assignee Address: US CA Brisbane US CA Novato US MN Rochester
- Agency: Wilson Sonsini Goodrich & Rosati
- Agent Michael Schiff
- Main IPC: A61K31/496
- IPC: A61K31/496 ; A61K31/728 ; A61K31/4178 ; A61K9/00

Abstract:
Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
Public/Granted literature
- US20180117038A1 TREATMENT OF OPHTHALMIC CONDITIONS BY SELECTIVELY REMOVING SENESCENT CELLS FROM THE EYE Public/Granted day:2018-05-03
Information query
IPC分类: